69 related articles for article (PubMed ID: 23866929)
1. Case report: Efficacy of icotinib treatment in lung adenocarcinoma with esophageal squamous cell carcinoma: a rare case of double primary malignant tumors.
Deng M; Li X; Mu H; Wei M; Sun L
Front Med (Lausanne); 2024; 11():1266062. PubMed ID: 38606154
[TBL] [Abstract][Full Text] [Related]
2. Mixed adenocarcinoma-neuroendocrine carcinoma of the cervix with pulmonary metastasis: A case report and literature review.
Cai H; Zhou K; Luo L
Asian J Surg; 2024 May; ():. PubMed ID: 38796365
[No Abstract] [Full Text] [Related]
3. Mixed large cell neuroendocrine carcinoma and mucosa-associated lymphoid tissue lymphoma of the lung: A case report.
Matsumoto T; Imai Y; Kosaka Y; Shintani T; Tomii K
Oncol Lett; 2015 May; 9(5):2068-2072. PubMed ID: 26137014
[TBL] [Abstract][Full Text] [Related]
4. De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors.
Le X; Desai NV; Majid A; Karp RS; Huberman MS; Rangachari D; Kent MS; Gangadharan SP; Folch E; VanderLaan PA; Costa DB
Lung Cancer; 2015 Apr; 88(1):70-3. PubMed ID: 25700797
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine Kinase Inhibitors in EGFR-Mutated Large-Cell Neuroendocrine Carcinoma of the Lung? A Case Report.
Aroldi F; Bertocchi P; Meriggi F; Abeni C; Ogliosi C; Rota L; Zambelli C; Bnà C; Zaniboni A
Case Rep Oncol; 2014 May; 7(2):478-83. PubMed ID: 25202262
[TBL] [Abstract][Full Text] [Related]
6. A prognostic nomogram based on least absolute shrinkage and selection operator Cox regression in patients with pulmonary large-cell neuroendocrine carcinoma.
Zhang T; Mao Z; Ma M; Li G; Qiao X; Wang H
Transl Cancer Res; 2024 Feb; 13(2):916-934. PubMed ID: 38482439
[TBL] [Abstract][Full Text] [Related]
7. Successful Treatment of Combined Large Cell Neuroendocrine Carcinoma Harboring an EGFR Mutation with
Muto S; Ozaki Y; Okabe N; Matsumura Y; Hasegawa T; Shio Y; Hashimoto Y; Suzuki H
Case Rep Oncol; 2020; 13(3):1387-1392. PubMed ID: 33442360
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations.
Rekhtman N; Pietanza CM; Sabari J; Montecalvo J; Wang H; Habeeb O; Kadota K; Adusumilli P; Rudin CM; Ladanyi M; Travis WD; Joubert P
Mod Pathol; 2018 Jan; 31(1):111-121. PubMed ID: 28884744
[TBL] [Abstract][Full Text] [Related]
9. [Clinical Analysis of 22 Cases of Pulmonary Large Cell Neuroendocrine Cancer].
Qian Z; Hu Y; Zheng H; Dong Y; Wang Q; Li B
Zhongguo Fei Ai Za Zhi; 2016 Feb; 19(2):82-7. PubMed ID: 26903161
[TBL] [Abstract][Full Text] [Related]
10. Assessment and prognostic analysis of EGFR mutations or/and HER2 overexpression in Uygur's Non-small Cell Lung Cancer.
Shen H; Du G; Liu Z; Bao J; Yu Q; Jia C; Liang X; Shan L
Int J Clin Exp Med; 2015; 8(12):22300-9. PubMed ID: 26885207
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy.
Fasano M; Della Corte CM; Papaccio F; Ciardiello F; Morgillo F
J Thorac Oncol; 2015 Aug; 10(8):1133-41. PubMed ID: 26039012
[TBL] [Abstract][Full Text] [Related]
12. Treatment options for patients with large cell neuroendocrine carcinoma of the lung.
Iyoda A; Makino T; Koezuka S; Otsuka H; Hata Y
Gen Thorac Cardiovasc Surg; 2014 Jun; 62(6):351-6. PubMed ID: 24719260
[TBL] [Abstract][Full Text] [Related]
13. Large-cell neuroendocrine carcinoma (LCNEC) without pulmonary symptoms diagnosed in a cutaneous metastasis.
Yuan C; Keating B; Farricielli LA; Zhang K
Am J Case Rep; 2014; 15():97-102. PubMed ID: 24624250
[TBL] [Abstract][Full Text] [Related]
14. Large-cell neuroendocrine carcinoma of lung with epidermal growth factor receptor (EGFR) gene mutation and co-expression of adenocarcinoma markers: a case report and review of the literature.
Sakai Y; Yamasaki T; Kusakabe Y; Kasai D; Kotani Y; Nishimura Y; Itoh T
Multidiscip Respir Med; 2013 Jul; 8(1):47. PubMed ID: 23866929
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
Chung C
J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
[TBL] [Abstract][Full Text] [Related]
17. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
[TBL] [Abstract][Full Text] [Related]
18. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
Chen K; Yu X; Wang H; Huang Z; Xu Y; Gong L; Fan Y
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1179-1187. PubMed ID: 29063948
[TBL] [Abstract][Full Text] [Related]
19. Surgical resection of advanced non-small cell lung cancer after a response to EGFR-TKI: presentation of two cases and a literature review.
Yamamoto Y; Kodama K; Maniwa T; Takeda M
J Cardiothorac Surg; 2017 Nov; 12(1):98. PubMed ID: 29169381
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
